Whalesbook: AI-Powered Stock Updates via WhatsApp

Stock Analysis

Description

Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.

Key Growth Triggers

Currently no data available for Key Growth Triggers.

Order Book

Currently no data available for Order Book.

Key Red Flags

Currently no data available for Key Red Flags.

Key Dates To Watch

Currently no data available for Key Dates To Watch.

Corporate Announcements

6th Apr 26

Impact Rating: 3

Thyrocare Technologies Limited informed exchanges about SEBI Regulation 74(5) for Q4 FY26. The company confirmed its shares are entirely in demat form with no rematerialization requests received.

1st Apr 26

Impact Rating: 7

Docon Technologies Private Limited updated disclosures on Thyrocare Technologies shares after API Holdings' partial redemption of INR 1,200 million debentures. The face value per debenture reduced from INR 10,00,000 to INR 9,00,000.

29th Mar 26

Impact Rating: 6

Thyrocare Technologies has been issued an Income Tax demand notice for ₹202.82 lakh (₹2.03 cr) for Assessment Year 2024-25. The company affirms no material impact and intends to contest the demand.

23rd Mar 26

Impact Rating: 5

Complying with SEBI rules, Thyrocare Technologies will shut its trading window for insiders from April 1, 2026. The closure lasts until 48 hours post announcement of financial results for the quarter and year ending March 31, 2026.

2nd Mar 26

Impact Rating: 6

Thyrocare approved allotment of 3,624 equity shares under its Employee Stock Option Scheme (ESOS). This raises total issued share capital to ₹15,916.53 lakh (₹159.17 cr) comprising 15,91,65,315 shares.

Peer Comparision

S.No.	Name	Current Price (Rs.)	Price to Earning	Market Capitalization (Rs.Cr.)	Dividend yield (%)	Net Profit latest quarter (Rs.Cr.)	YOY Quarterly profit growth (%)	Sales latest quarter (Rs.Cr.)	YOY Quarterly sales growth (%)	Return on capital employed (%)	Sales (Rs.Cr.)	OPM (%)	Profit after tax (Rs.Cr.)	Profit after tax latest quarter (Rs.Cr.)	Price to book value	Return on assets (%)	Debt to equity
1.	Dr Lal Pathlabs	1479.50	46.41	24795.04	0.81	152.20	16.41	730.60	10.66	28.88	2599.70	28.44	534.30	150.40	10.38	19.11	0.07
2.	Vijaya Diagnost.	1025.00	69.08	10530.30	0.19	43.28	2.75	201.56	10.17	20.91	731.83	39.81	152.42	43.28	12.18	12.29	0.42
3.	Metropolis Healt	1992.60	65.41	10351.04	0.20	52.89	13.22	429.19	22.70	14.66	1483.31	22.40	158.23	52.67	7.20	8.24	0.14
4.	Thyrocare Tech.	462.00	61.23	7355.63	1.52	43.03	45.42	202.23	24.03	26.50	707.54	31.28	120.13	43.03	14.22	14.10	0.04
5.	Nephrocare Health Services	503.10	75.96	5052.76	0.00	14.23	–	473.50	–	14.11	755.81	22.05	66.52	14.23	–	7.39	0.36
6.	Krsnaa Diagnost.	749.75	28.55	2440.85	0.37	23.24	5.78	182.88	2.33	12.52	698.31	29.97	85.47	23.24	2.61	6.46	0.30
7.	Suraksha Diagno.	277.80	45.35	1448.14	0.00	8.83	-13.06	78.73	17.95	17.84	275.92	30.91	31.93	8.99	6.28	9.83	0.51
–	Median: 13 Co.	503.1	36.95	1448.14	0.0	18.15	13.22	192.22	16.3	25.75	698.31	29.93	49.1	17.7	6.28	14.1	0.14

Quarterly Results

Standalone figures in ₹ crores

	Dec 2022	Dec 2023	Dec 2024	Jun 2023	Jun 2024	Jun 2025	Mar 2023	Mar 2024	Mar 2025	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales	117	123	153	124	144	179	125	141	174	125	136	163	202
Expenses	91	92	112	90	101	122	102	108	118	96	100	114	133
Operating Profit	26	31	40	33	42	57	23	34	56	30	37	49	69
Other Income	1	2	4	0	3	4	2	3	5	1	2	2	2
Profit before tax	18	21	28	24	35	51	15	25	48	22	28	40	61
Tax %	28%	28%	32%	31%	28%	29%	33%	23%	54%	35%	28%	27%	29%
Net Profit	13	15	19	17	25	36	10	19	22	14	20	30	43
EPS in Rs	0.80	0.94	1.20	1.05	1.58	2.27	0.63	1.21	1.38	0.90	1.28	1.86	2.71

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	150	180	235	298	332	370	401	474	562	486	524	633	708
Expenses	81	109	140	182	193	222	233	304	330	371	388	446	486
Operating Profit	69	71	95	115	139	148	168	171	232	115	136	188	221
Other Income	7	13	6	-16	21	14	-35	12	7	5	6	13	14
Interest	0	0	1	0	0	0	1	1	3	5	5	3	2
Depreciation	6	11	11	12	12	14	20	21	28	34	39	47	46
Profit before tax	69	73	89	87	148	147	112	161	207	81	98	151	188
Net Profit	46	49	59	47	96	95	79	120	152	57	71	96	120
EPS in Rs	14.07	3.25	3.64	2.90	5.96	6.01	5.00	7.55	9.58	3.59	4.48	6.02	7.56
Dividend Payout %	0%	157%	91%	115%	56%	111%	33%	110%	52%	167%	134%	116%	–

Balance Sheet

Standalone figures in ₹ crores

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	11	51	54	54	54	53	53	53	53	53	53	53	53
Reserves	195	229	322	364	400	403	325	393	468	468	461	484	463
Borrowings	25	0	0	0	0	0	9	10	21	21	39	23	22
Other Liabilities	14	14	39	26	31	32	55	73	55	70	68	116	113
Total Liabilities	246	293	414	444	485	488	442	528	597	612	620	676	651
Fixed Assets	87	83	93	89	103	108	112	119	149	157	159	158	160
Gross Block	104.75	109.81	131.07	100.90	125.86	145.42	167.12	192.94	246.29	278.95	301.54	341.27	–
Accumulated Depreciation	17.42	26.77	38.49	11.69	22.90	37.16	55.56	73.79	96.90	122.28	142.25	183.72	–
CWIP	6	6	1	2	0	1	4	8	2	1	1	14	3
Investments	119	162	266	299	315	289	239	274	259	274	291	284	265
Other Assets	33	42	55	54	68	89	88	127	186	180	169	221	223
Total Assets	246	293	414	444	485	488	442	528	597	612	620	676	651

Cash Flows

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	46	36	67	89	112	97	136	111	106	120	155	191
Cash from Investing Activity	-52	-21	-19	-40	-48	-3	27	-53	-12	-32	-80	-55
Cash from Financing Activity	0	-23	-45	-48	-65	-96	-163	-58	-87	-88	-84	-124
Net Cash Flow	-6	-7	3	1	-1	-3	1	0	6	1	-9	12

Ratios

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	12	9	11	7	10	11	14	34	60	63	28	40
Inventory Days	54	47	54	64	66	54	60	50	54	63	106	93
Days Payable	13	5	8	4	23	19	62	48	30	52	83	141
Cash Conversion Cycle	53	51	57	68	53	46	12	37	84	74	51	-9
Working Capital Days	22	52	15	28	11	4	-12	7	45	34	14	18
ROCE %	33%	27%	27%	29%	33%	31%	36%	37%	41%	15%	18%	26%

Shareholding Pattern

Numbers in percentages

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	71.14%	71.14%	71.14%	71.14%	71.11%	71.11%	71.11%	71.11%	71.06%	71.06%	71.06%	71.06%	60.93%
FIIs	10.13%	9.99%	3.44%	3.46%	3.35%	2.90%	2.49%	1.93%	2.77%	2.41%	3.23%	4.85%	5.32%
DIIs	8.68%	8.45%	13.46%	13.33%	13.89%	14.88%	14.89%	14.79%	14.68%	14.97%	14.54%	13.47%	20.16%
Public	10.04%	10.40%	11.95%	12.08%	11.64%	11.11%	11.49%	12.15%	11.49%	11.57%	11.18%	10.61%	13.58%